Etanercept biosimilar (Qilu Pharmaceutical)

依那西普生物类似药（齐鲁制药）

Report date: 2023/12/25 14:20:33

Base Information

Drug NameEtanercept biosimilar (Qilu Pharmaceutical)
Drug Alias Name重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白（齐鲁制药）Etanercept follow-on biologic (Qilu Pharmaceutical)rhTNFR:Fc (Qilu Pharmaceutical)Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ:IgG Fc Fusion Protein (Qilu Pharmaceutical)QL-0902
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A